Treace Medical Concepts shares are trading lower after the company reported worse-than-expected Q2 EPS results. Also, Truist Securities lowered its price target on the stock from $9 to $7.5.
Portfolio Pulse from Benzinga Newsdesk
Treace Medical Concepts shares are trading lower after the company reported worse-than-expected Q2 EPS results. Additionally, Truist Securities lowered its price target on the stock from $9 to $7.5.
August 07, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Treace Medical Concepts shares are trading lower due to worse-than-expected Q2 EPS results. Truist Securities also lowered its price target on the stock from $9 to $7.5.
The disappointing Q2 EPS results directly impact investor sentiment negatively. The price target cut by Truist Securities further exacerbates the negative outlook, likely leading to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100